Nasal Vaccine against Coronavirus Further Improved

Research team at Freie Universität Berlin increases safety of attenuated live SARS-CoV-2 vaccine. After having successfully tested a mucosal vaccine against coronavirus in animals just months ago, Berlin scientists have now further developed their live SARS-CoV-2 vaccine. Researchers at Freie Universität Berlin have increased the safety of the vaccine, which is administered via the nose. The results of their study on the modified form of the live vaccine have been published in Molecular Therapy ( https://doi.org/10.1016/j.ymthe. In early April 2023, a team of scientists from several Berlin research institutions presented a live SARS-CoV-2 vaccine in the journal Nature Microbiology , which has superior efficacy compared to intramuscularly administered vaccines. In preclinical trials, this vaccine, administered via the nose, produced better immunity at the mucous membranes of the respiratory tract than vaccines administered intramuscularly that were previously being used. The nasal vaccine described in Nature Microbiology is a so-called live-attenuated vaccine.